More info on the EACTS annual edition
Learn MoreWhere to find us at EACTS Booth
See Our location
|
|
|
||
---|---|---|---|---|
15:10 - 18:00 | Atrioventricular valves – valves | Techno College |
|
|
|
|||
---|---|---|---|---|---|
08:15 – 09:45 | Evidence beyond the use of bioprosthesis | Botticelli | |||
5-years hemodynamic performance of three aortic
bioprostheses.
A randomized clinical trial More information INDURE registry: Clinical and Quality of Life Outcomes of surgical aortic valve replacement in 421 patients under 60 years of age More information PERIMOUNT Magna Ease vs INSPIRIS RESILIA Aortic Valve in patients below 70 years of age: a propensity-matched analysis of the haemodynamic performances More information Extracted from the 2022 EACTS program, focusing on heart valve disease and devices. All abstracts have been extracted from the EACTS website |
|||||
08:15 – 09:45 | Deep dive in mitral pathologies | Amber 1 & 2 | |||
Standardized subannular repair in type IIIb mitral
regurgitation:
1-year results from REFORM-MR Registry More information Extracted from the 2022 EACTS program, focusing on heart valve disease and devices. All abstracts have been extracted from the EACTS website |
|||||
10:15 – 11:45 | Controversies in mitral disease | Michelangelo | |||
14:15 – 17:30 | Bioprosthetic structural aortic valve degeneration: from incidence to management | Auditorium | |||
Late Clinical and Echocardiographic Results with
the Magna Ease© Pericardial Aortic Bioprosthesis
More information Extracted from the 2022 EACTS program, focusing on heart valve disease and devices. All abstracts have been extracted from the EACTS website |
|||||
16:15 – 17:45 | Beyond stereotypes in tricuspid surgery | Amber 1 & 2 |
|
|
|
||
---|---|---|---|---|
08:15 – 09:45 | Minimally invasive aortic valve replacement, repair, and sparing: feasible, safe, or both? | Auditorium | ||
16:00 – 17:30 | Evaluating and solving problems around aortic valve replacement | Michelangelo | ||
Mid-Term Echocardiographic Results of the INSPIRIS
RESILIA Aortic Valve –
a Retrospective Comparison to the Carpentier Edwards Magna Ease More information Multicenter, large scale, propensity-weighted comparison of three aortic bioprostheses: conventional stented, new-generation stented and rapid-deployment More information Propensity Score Analysis of Stented vs Rapid Deployment Aortic Bioprostheses in Patients with Small Aortic Annulus More information Extracted from the 2022 EACTS program, focusing on heart valve disease and devices. All abstracts have been extracted from the EACTS website |
||||
16:00 – 16:30 | TAVI – Where do we stand? Where do we want to go? | Amber 1 & 2 | ||
16:00 – 17:00 | Clinical practice guidelines; how are they constructed? What makes a strong recommendation? ESC / EACTS 2021 Joint ESC / EACTS valvular heart guidelines | Amber 4 |
|
|
|
||
---|---|---|---|---|
08:30 – 10:00 | New options for imaging in planning and performance of transcatheter treatment, including remote proctoring | Amber 1 & 2 | ||
10:30 – 12:00 | Clinical trial updates | Auditorium |
No clinical data are available that evaluate the long term impact of RESILIA tissue in patients.
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).Skip